RDY · Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Limited has furnished a presentation on its audited financial results for the fourth quarter and full fiscal year ended March 31, 2026, as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This disclosure, enclosed as Exhibit 99.1, provides investors with detailed insights into the company's financial performance for the period, including key income statement metrics, operational highlights, and any relevant management commentary typically found in such presentations. The filing was addressed to major exchanges including National Stock Exchange of India (DRREDDY), BSE Limited (500124), New York Stock Exchange (RDY), and NSE IFSC Ltd (DRREDDY), ensuring broad dissemination to shareholders and market participants. Signed by Company Secretary, Compliance Officer, and Head-CSR K Randhir Singh, this intimation underscores the company's commitment to timely and transparent reporting of material financial information. Investors should review Exhibit 99.1 for specifics on revenue, profitability, EPS, and year-over-year comparisons, which are critical for assessing quarterly and annual performance trends.